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AggregometryAbstract Antiplatelet drugs play a pivotal role in the management of patients with acute coronary
syndrome. Clopidogrel is an important antiplatelet drug commonly used in the treatment of those
patients. However, the variability in patient response to clopidogrel is worrisome because a
decreased response may lead to unfavorable clinical outcomes. Thus, it is crucial to study possible
ways to overcome this problem. In the current study, we measured platelet aggregation in vitro to
identify patients with clopidogrel resistance. Those patients were given double the standard main-
tenance dose of clopidogrel and platelet aggregation was reassessed. It was found that there was a
signiﬁcant increase in clopidogrel response (p< 0.001). Therefore, we recommend that using dou-
ble the standard maintenance dose of clopidogrel should be considered in those patients.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
The formation of an acute thrombus on a ruptured coronary
atherosclerotic lesion leads to the onset of acute coronary syn-
dromes (ACSs).13 These thrombotic episodes largely occur in
response to atherosclerotic lesions that have progressed to a
high-risk inﬂammatory prothrombotic stage.22
Vascular intimal injury exposes thrombogenic subendothe-
lial substances (e.g., collagen) to ﬂowing blood. Circulating
platelets adhere to the site of injury then become activated.14
Additional platelets are recruited from the circulation to the
site of vascular injury, leading to the formation of an occlusiveplatelet thrombus. Platelet activation occurs as a result of the
combined actions of several agonists that bind to their respec-
tive membrane receptors on adherent platelets.12
ADP is a platelet activator that is released from red blood
cells, activated platelets, and damaged endothelial cells. It in-
duces platelet adhesion and aggregation.15 It also ampliﬁes
the response to other agonists thereby contributing to the
growth and stability of a thrombus.1 ADP interacts with
P2Y12 receptor on the surface of platelets.
7
Clopidogrel is one of the series of thienopyridine com-
pounds developed as antagonists of P2Y12 and thus effectively
inhibits platelet activation. It is a prodrug and needs to be acti-
vated in vivo to form an active metabolite that binds irrevers-
ibly and selectively to the P2Y12 receptors, and thereby
prevents signal transduction.10
Inhibition of platelet aggregation by clopidogrel is highly
variable and shows a normal distribution with an average of
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phenomenon including drug–drug interactions, noncompli-
ance, variability in P2Y12 receptor number and its afﬁnity for
the active metabolite of clopidogrel, and variability in the for-
mation of the active metabolite. Clopidogrel is metabolized by
the cytochrome P 450 enzyme system. It has been proposed that
CYP2C19 is the major enzyme involved in the generation of
clopidogrel active metabolite. There is a wide genetic variation
in the activity of this enzyme in the population and conse-
quently, the activity of clopidogrel is similarly heterogeneous.4,9
The problem of clopidogrel resistance may be managed by
simply increasing the dose of clopidogrel or by switching to
newer ADP antagonists. However, the most suitable approach
is still to be deﬁned.
2. Patients and methods
This study included 100 patients diagnosed with acute coro-
nary syndrome admitted to Maadi Military Hospital from Sep-
tember 2008 to 2009. The laboratory tests were done in Central
laboratories of Ministry of Health.
All male or female patients between the ages of 25 and
75 years with documented acute coronary syndrome were in-
cluded. Patients with previous instent stenosis and patients
with previous CABG were excluded.
Patientswere subjected tomedical history taking,ECGand lab-
oratory investigations including CBC, cardiac enzymes, liver and
kidney functions. All patients were taking aspirin 150 mg/day.
2.1. Light transmission aggregometry
This testwas done to assess platelet aggregation in vitro. The test
was done on all patients immediately before giving a clopidogrel
loading dose of 300 mg. The test was repeated after the ﬁrst
maintenance clopidogrel of 75 mg 24 h after loading. Clopido-
grel resistant patients were then identiﬁed according to the crite-
ria mentioned later on. Those patients were given a double
clopidogrel dose of 150 mg and the test was repeated on them.
2.1.1. Specimen
4.5 ml of blood was collected immediately into plastic tubes
containing 0.5 ml sodium citrate 3.8%. The test was done with-
in 2 h after specimen collection.
2.1.2. Procedure
Platelet aggregation is performed utilizing platelet-rich plasma
(PRP), whichwas obtained as a supernatant after centrifugation
of citrated blood at 800 rpm for 10 min. Platelet-poor plasma
was obtained by a second centrifugation of the blood fraction
at 2500 rpm for 10 min. The platelet count in PRP was adjusted
to the range of 250.000/ll by dilution with autologous plasma.
For each test, standardized amounts of platelet-rich plasma
and platelet poor plasmawere added to separate curettes to pro-
vide a baseline control for maximum andminimum aggregation
respectively. The reagent adenosine diphosphate (A.D.P.) (Dia
Med) was added and the degree of aggregation is determined
by an aggregationmeter whichmeasures changes in optical den-
sity as platelets begin to clump. Platelet aggregation was deter-
mined as the maximal percent change in light transmittance
from baseline using platelet-poor plasma as a reference.22.1.3. Interpretation of results
Clopidogrel response was determined according to the degree
of inhibition of platelet aggregation deﬁned as the absolute
reduction in platelet ADP induced aggregation compared with
baseline values. Patients were classiﬁed as responders when
there is P30% inhibition, low responders when there is 10–
29% inhibition and non responders when there is <10% inhi-
bition of aggregation. Low responders and non responders
were considered clopidogrel resistant patients.17
2.2. Statistical analysis
Data were analyzed by Statistical Package for Social Science
(SPSS) version 13. Parametric data were expressed as
mean ± SD. Wilcoxon signed rank test was used to compare
variables. P value <0.05 is considered signiﬁcant.18
3. Results
One hundred patients were included in the study. The mean
age of the patients is 53.1 (±10). The minimum age is 33 years
old and the maximum is 74 years old.
Seventy-eight patients (78%) were found to be responders
to clopidogrel (P30% inhibition) and twenty-two patients
(22%) were found to be resistant, 17 of them were low
responders (10–29% inhibition of aggregation) and 5 were
non responders to clopidogrel (<10% inhibition). This is
shown in Fig. 1.
After giving the 22 patients with clopidogrel resistance
(mean inhibition of 15.7%±5) the double dose of clopidogrel,
it was found that 12 patients were responders, 9 were low
responders and 1 patient was non responder, with a mean inhi-
bition of 31.6% ±7 (p< 0.001). This is shown in Fig. 2.
Twelve of the 17 patients who were initially low responders be-
came responders and 5 remained as low responders. Also, 4 of
the 5 patients who were initially non responders became low
responders and only one patient remained non responder.
4. Discussion
Antiplatelet therapies, including aspirin and thienopyridines,
are key components of pharmacotherapy in acute coronary
syndromes (ACS) and PCI.16 When combined with aspirin,
clopidogrel provides additive reduction in the risk of ischemic
events in patients with non-ST-elevation ACS and in patients
undergoing PCI.5 In addition, clopidogrel helps to maintain
infarct-related artery patency and clinical outcomes in patients
with ST-elevation MI receiving ﬁbrinolytic therapy.
Despite improved outcomes with modern-day therapies, 8–
10% of patients experience a recurrent CV event during the
ﬁrst year after ACS, in addition, 1–3% of patients have suba-
cute stent thrombosis after PCI with potentially catastrophic
consequences, including a high risk of early mortality.21
Several studies have demonstrated substantial interpatient
variability in measures of platelet inhibition after treatment
with clopidogrel. The prevalence of individuals who are deemed
to have an inadequate response to clopidogrel varies between
4% and 34%, depending on the method of testing and the def-
inition of resistance or hyporesponsiveness used in the individ-
ual analyses. Differences in assays of agonist concentrations
Figure 1 Clopidogrel response with standard dose in all studied patients.
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Figure 2 Platelet inhibition before and after doubling the
maintenance dose of clopidogrel in clopidogrel resistant patients.
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prevalence of these conditions.24 As such, there remains no
clear consensus on the deﬁnition of clopidogrel resistance.
Moreover, the question remains whether this phenomenon
can infact be blamed for clinical failures. For this reason we
believe that the term clopidogrel resistance should be limited
to those who fail to achieve a desired pharmacological re-
sponse to drug therapy rather than patients who experience
recurrent ischemic events while on clopidogrel.24
In the present study, platelet aggregation was measured in
100 patients suffering from ACS by platelet aggregometry test
before and after giving loading dose of 300 mg clopidogrel and
a maintenance dose of 75 mg to all patients.
It was found that 78 patients are responders (>30% inhibi-
tion of platelet aggregation from base line), 17 patients are low
responders (P10%, <30% inhibition of platelet aggregation)
and 5 patients are non responders (<10% inhibition of plate-let aggregation). On doubling the dose of clopidogrel in clop-
idogrel resistant patients, 12 were found to be responders, 9
were low responders and 1 was non responder (p< 0.001).
This is in agreement with the study of Aleil et al.,3 in which
153 elective percutaneous coronary intervention patients were
randomized to clopidogrel 150 mg/day n= 58 or 75 mg/day
n= 95 for 4 weeks. All patients received aspirin 75 mg/day.
After 2 weeks, the proportion of low responders was signiﬁ-
cantly lower in patients randomized to clopidogrel 150 mg/
day than in those randomized to clopidogrel 75 mg/day
(p= 0.0004). In the clopidogrel 75 mg/day group, 64.5% (20
of 31) of low responders became responders after switching
to clopidogrel 150 mg/day for 2 weeks.
Furthermore, von Beckerath et al.23 studied the effect of
increasing the clopidogrel maintenance dose in sixty patients
after pre-treatment with 600 mg of clopidogrel within 12 h
after successful PCI. Patients were allocated to receive clopido-
grel daily maintenance doses of 75 or 150 mg for 30 days in a
double-blind randomized trial. ADP-induced platelet aggrega-
tion 30 days after PCI in the group treated with 150 mg/day
clopidogrel was signiﬁcantly lower than in the group treated
with 75 mg/day (P< 0.001). This result shows that adminis-
tration of 150 mg daily maintenance dose of clopidogrel results
in more intense inhibition of platelet function.
In a different study, Cuisset et al.6 assessed platelet re-
sponse to clopidogrel and aspirin in patients with non ST-ele-
vation ACS undergoing PCI with stenting (n= 106).
According to their ADP-induced maximal intensity of platelet
aggregation, patients were stratiﬁed into four quartiles;
38 ± 8%, 56 ± 4%, 66 ± 4% and 82 ± 12%. Patients in
the fourth quartile were deﬁned as clopidogrel low responders.
The range of values for this fourth quartile was 70–108%
which was similar to the normal range (69–104%) deﬁned from
a healthy population of 30 subjects and used in clinical practice
as reference values. They found after one month follow-up a
signiﬁcant association of adverse clinical events in patients in
the 4th quartile vs. quartile 1–3.
There are several methods to measure platelet reactivity. In
addition to light transmission aggregometry which was used in
262 J.I. Louca et al.this study, tests like P2Y12 assay, and genetic testing can also
be used19. In the GRAVITAS trial, P2Y12 assay by a turbi-
dimetry-based optical detection system that measures plate-
let-induced aggregation, was the test used to assess platelet
reactivity on clopidogrel. It was found that there was a signif-
icant reduction in platelet reactivity by pharmacologic testing
in the group on a clopidogrel maintenance dose of 150 mg dai-
ly when compared to the standard dose of 75 mg daily. How-
ever, they did not ﬁnd signiﬁcant difference in clinical
outcomes between the two groups20. Genetic testing for
CYP2C19 genotype, on the other hand, has also been used
in several other studies to evaluate platelet reactivity when
using clopidogrel. In a meta analysis, Holmes et al. suggested
that there is no clinically important association of CYP2C19
genotype with cardiovascular outcomes.11
Finally, this study shows that, based on laboratory testing,
it appears that doubling the maintenance dose of clopidogrel is
a reasonable option for patients with clopidogrel resistance.
However, further studies to prove improvement in the clinical
outcome in those patients are still needed.Conﬂict of interest
Authors declare that there is no conﬂict of interest.
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